OncoZenge takes SEK 2M bridge loan to fund Phase III until rights issue
What's the deal? OncoZengeDealroom has a profile for this one. Try Dealroom →, a Stockholm-based clinical-stage pharmaceutical company, has raised a SEK 2.0 million (≈$210,000) bridge loan from John HaurumDealroom has a profile for this one. Try Dealroom →. The financing covers the company's liquidity needs until it completes a planned rights issue of roughly SEK 33.3 million.
Why now? OncoZenge announced the rights issue on August 25, 2026, and signed the bridge loan three days later. The loan was disbursed the same day, on August 28.
The terms: The lender receives a 5% arrangement fee and 1.5% monthly interest. Haurum may request that the outstanding amount, plus accrued interest, be set off against new shares via a directed issue priced at the rights issue level — though the board is not obligated to approve one. Directors said the loan was struck "on market terms."
What's the endgame? OncoZenge is developing BupiZenge, a bupivacaine lozenge for oral pain in conditions such as oral mucositis from cancer therapy, positioned as an alternative to systemic opioids. It recently won European regulatory approval to start its pivotal Phase III trial, "BEAM-Pain," which has enrolled its first patient with site activations ongoing.
Stockholm Corporate FinanceDealroom has a profile for this one. Try Dealroom → is financial adviser and Fredersen AdvokatbyråDealroom has a profile for this one. Try Dealroom → legal adviser on the rights issue, with Vator SecuritiesDealroom has a profile for this one. Try Dealroom → as issuing agent. OncoZenge trades on Nasdaq First North Growth MarketDealroom has a profile for this one. Try Dealroom → under the ticker ONCOZ.
The signal: The stopgap loan underscores how tightly capital and clinical timelines are linked for small-cap drug developers. With a Phase III study just underway, OncoZenge needs to keep the lights on until its far larger rights issue lands.
Read more: view.news.eu.nasdaq.com
Image credit: Generated with Gemini
